Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20713741 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL24633719 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL4084639 | 0.89 | PIK3CD (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL4498311 | 0.89 | PIK3CD (0.45) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL1002266 | 0.87 | PIK3CD (0.58) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL13662060 | 0.87 | PIK3CD (0.58) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL13748623 | 0.87 | PIK3CD (0.58) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL1002636 | 0.87 | PIK3CD (0.58) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL29770788 | 0.86 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL29058378 | 0.86 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | CHRM2 2089/4885CHRM1 1068/4885CHRM3 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.